Paul Tudor Jones Nuvalent, Inc. Transaction History

Tudor Investment Corp Et Al

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $1.27 Million - $1.65 Million	-20,254 Reduced 61.3%	12,788 $970,000
Q1 2024 May 15, 2024	BUY	$72.35 - $88.99 $279,560 - $343,857	3,864 Added 13.24%	33,042 $2.48 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $410,201 - $776,307	9,670 Added 49.57%	29,178 $2.15 Million
Q3 2023 Nov 15, 2023	SELL	$39.12 - $49.85 $241,448 - $307,674	-6,172 Reduced 24.03%	19,508 $896,000
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $399,256 - $756,521	16,932 Added 193.55%	25,680 $1.08 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $222,374 - $293,232	8,748 New	8,748 $228,000

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.08B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.